Victor N Sakran

Array ( [id] => 19752826 [patent_doc_number] => 20250041391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II [patent_app_type] => utility [patent_app_number] => 18/927301 [patent_app_country] => US [patent_app_date] => 2024-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18927301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745670 [patent_doc_number] => 20250034235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => COMPOSITIONS FOR PREVENTING OR TREATING INFLUENZA INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/914010 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18914010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19724071 [patent_doc_number] => 20250026822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => METHODS OF TREATING OR PREVENTING A COMPLICATION OF SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 18/909225 [patent_app_country] => US [patent_app_date] => 2024-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18909225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862308 [patent_doc_number] => 20250101094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => ANTI IL-6 DOMAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/830877 [patent_app_country] => US [patent_app_date] => 2024-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18830877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116048 [patent_doc_number] => 12365737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Anti-IL-18BP antibodies [patent_app_type] => utility [patent_app_number] => 18/817109 [patent_app_country] => US [patent_app_date] => 2024-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 21 [patent_no_of_words] => 34272 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18817109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108493 [patent_doc_number] => 12359202 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping [patent_app_type] => utility [patent_app_number] => 18/773461 [patent_app_country] => US [patent_app_date] => 2024-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 14 [patent_no_of_words] => 29853 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18773461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556466 [patent_doc_number] => 20240368258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78 [patent_app_type] => utility [patent_app_number] => 18/771877 [patent_app_country] => US [patent_app_date] => 2024-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -115 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18771877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023218 [patent_doc_number] => 20250161440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OF PSORIASIS [patent_app_type] => utility [patent_app_number] => 18/750581 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18750581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19684016 [patent_doc_number] => 20250002561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => MODIFIED IMMUNOGLOBULIN FC REGIONS [patent_app_type] => utility [patent_app_number] => 18/739702 [patent_app_country] => US [patent_app_date] => 2024-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18739702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448973 [patent_doc_number] => 20240309103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ANTI-NPR1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/680910 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599609 [patent_doc_number] => 20240390489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/674399 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601109 [patent_doc_number] => 20240391989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHODS FOR INHIBITING MYOSTATIN ACTIVATION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/646693 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541791 [patent_doc_number] => 20240358827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => STABLE LIQUID FORMULA [patent_app_type] => utility [patent_app_number] => 18/638633 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658520 [patent_doc_number] => 20240425585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/632662 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18632662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379375 [patent_doc_number] => 20240269245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME [patent_app_type] => utility [patent_app_number] => 18/615520 [patent_app_country] => US [patent_app_date] => 2024-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642936 [patent_doc_number] => 20240417456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 18/613481 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554928 [patent_doc_number] => 20240366720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [patent_app_type] => utility [patent_app_number] => 18/593002 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19691331 [patent_doc_number] => 20250009876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/581446 [patent_app_country] => US [patent_app_date] => 2024-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 105327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581446 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318366 [patent_doc_number] => 20240239909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => Antagonistic CD40 Monoclonal Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/441998 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380975 [patent_doc_number] => 20240270845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTI-CD2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/439510 [patent_app_country] => US [patent_app_date] => 2024-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439510 [rel_patent_id] =>[rel_patent_doc_number] =>)